Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

欢迎关注凯莱英药闻2024年10月11日，辉瑞宣布，美国食品药品监督管理局 (FDA) 已批准 Hympavzi（marstacimab）的上市申请，用于预防或减少患有 A 型血友病（先天性第 VIII 因子缺乏症）和B 型血友病（先天性第 IX ...

纽约 - 辉瑞制药公司（NYSE: ...

▎药明康德内容团队编辑‍今天，美国FDA批准辉瑞（Pfizer）药品Hympavzi（marstacimab）用于常规预防或减少12岁及以上血友病A和血友病B成人和儿童患者的出血，这些患者体内不含凝血因子VIII与IX抑制剂（中和抗体）。根据新闻稿， ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

Hympavzi的成功获批，对于血友病患者而言，无疑是一种救赎。这款药物的推出，不仅象征着治疗手段的多元化，更为期待已久的患者带来了新的选择。长期以来，患者在治疗过程中面临许多痛苦，包括每周多次的静脉注射，而Hympavzi的自动注射方式极大地减轻了这种负担，可能使他们回归正常生活，让患者重拾对生活的信心。

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

当地时间10月11日，美国FDA批准辉瑞（Pfizer）药品Hympavzi（marstacimab）用于常规预防或减少12岁及以上血友病A和血友病B成人和儿童患者的出血，这些患者体内不含凝血因子VIII与IX抑制剂（中和抗体）。